All In Biotech

Drug Trial Radar · NCT00093795

Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Positive Breast Cancer

A Phase III, Adjuvant Trial Comparing Three Chemotherapy Regimens in Women With Node-Positive Breast Cancer: Docetaxel/Doxorubicin/Cyclophosphamide (TAC); Dose-Dense (DD) Doxorubicin/Cyclophosphamide Followed By DD Paclitaxel (DD AC→P); DD AC Followed By DD Paclitaxel Plus Gemcitabine (DD AC→PG)

Last checked: Nov 19, 2026Latest source record: Jan 11, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 4,894 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

4,894

Actual

Start

Oct 2004

Primary completion

Mar 2012

Study completion Jun 2016

Sponsor

Lead sponsor
NSABP Foundation IncResearch network
Sponsor type
Research network
Collaborators
National Cancer Institute (NCI)
First posted
Oct 8, 2004

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Drugs used in chemotherapy, such as docetaxel, doxorubicin , cyclophosphamide, paclitaxel, and gemcitabine work in different ways to stop tumor cells from dividing so they stop growing or die. Giving combination chemotherapy after surgery may kill any remaining tumor cells. PURPOSE: This randomized phase III trial is studying three different combination chemotherapy regimens and comparing how well they work in treating women who have undergone surgery for node-positive breast cancer.

Conditions

  • Breast Cancer

Interventions

  • CyclophosphamideDrug

    Group 1: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles Group 2 and Group 3: cyclophosphamide 600 mg/m2 IV every 14 days for 4 cycles

  • DocetaxelDrug

    75 mg/m2 IV every 21 days for 6 cycles

  • GemcitabineDrug

    2000 mg/m2 IV every 14 days for 4 cycles

  • PaclitaxelDrug

    175 mg/m2 IV every 14 days for 4 cycles

  • DoxorubicinDrug

    Group 1: 50 mg/m2 IV every 21 days for 6 cycles Group 2 and Group 3: 60 mg/m2 IV every 14 days for 4 cycles

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease-free Survival: Any Recurrence, Contralateral Breast Cancer, Second Primary Cancer, Death From Any Cause Prior to Recurrence or Second Primary CancerTime frame: 5 years

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • Lurleen Wallace Comprehensive Cancer at University of Alabama - Birmingham

    Birmingham, Alabama

  • Providence Cancer Center

    Anchorage, Alaska

  • Robert and Carol Weissman Cancer Center at Martin Memorial

    Stuart, Florida

  • Lucille P. Markey Cancer Center at University of Kentucky

    Lexington, Kentucky

  • South Shore Hospital

    South Weymouth, Massachusetts

  • Methodist Estabrook Cancer Center

    Omaha, Nebraska

  • CCOP - Northern New Jersey

    Hackensack, New Jersey

  • Blumenthal Cancer Center at Carolinas Medical Center

    Charlotte, North Carolina

  • Altru Cancer Center at Altru Hospital

    Grand Forks, North Dakota

  • Community Oncology Group at Cleveland Clinic Cancer Center

    Independence, Ohio

  • Chestnut Hill Healthcare Cancer Center

    Philadelphia, Pennsylvania

  • Madigan Army Medical Center - Tacoma

    Tacoma, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.